Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no personal rerequired to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for fo	rm 1449B/PTO	AUS 3 1	2004		Complete if Known	
	/3	į.		Application Number	10/019,342	
INFOR	MATION D	<b>ISC TOS</b>	SURE	Filing Date	12/21/2001	
STATE	MENT BY	APPLI	CANT	First Named Inventor	Richard S. Judson	
				Art Unit	1631	
(U	ise as many sheets a	is necessary)		Examiner Name	Marianne P. Allen	
Sheet	1	of	1	Attorney Docket Number	2458-4042US5	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
MIA	A	FISHER, LD AND VAN BELLE, G, Biostatistics: A Methodology for the Health Sciences, John Wiley & Sons, Inc. (New York, US), p. 158-161; p. 844-865, (1993).			

Examiner Signature	mealler	Date Considered	18/15/04	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2004	FORM PTO-	-1449		Attorney Docket: 2458-4042US5 Applicant: DENTON, et al.	Serial N 10/019,		
ANFOR	MATION DISCLO	SURE CITAT	TON	Filing Date: December 21, 2001	Group A	Art Unit:	
MARK	T 5 000 444						
mest	5,972,604	10/26/1999	Santamari				
<del></del>	5,858,659	01/12/1999	Sapolsky		<u> </u>		
<b> </b>	5,187,775	2/16/1993	Schroeder				
<del></del>	5,867,402	2/2/1999	Schneider				
<del></del>	6,023,659	2/8/2000	Sellhamer	ot at.			ļ <u>.</u>
<del></del>	5,096,557	03/17/1992 03/09/1993	Simons		<del></del>		
<del> </del>	5,612,179	03/18/1997	Simons		<del></del>	ļ	<u> </u>
	5,789,568	08/04/1998	Simons				
	5,851,762	12/22/1998	Simons			-	
<del></del>	5,724,253	3/3/1998	Skovira		<del></del>	<del></del>	
<del></del>	5,834,189	11/10/1998	Stevens et	al	<del></del>	<del></del>	
<del> </del>	5,618,672	4/8/1997	Stodola et		<del></del>	<del></del>	<del></del> -
	5,885,776	03/23/1999	Stone et a	· — 4	<del></del>	<del>                                     </del>	
	5,502,773	3/26/1996	Tibbetts e		<del></del>	<del> </del>	
Initial MPH	Patent Number WO 87/02802	Date 5/7/1987	PCT	Country	Class	Sub-Class	Trans
MIKE	) WO 87/02802	1 5/7/1987	I PCT				T V.
	DIO OTIOGRAM			· · · · · · · · · · · · · · · · · · ·	<del></del>		
	WO 91/05302	4/18/1991	PCT		<b>\</b>		Yes
	WO 92/01066	4/18/1991 1/23/1992	PCT PCT				Yes Yes
	WO 92/01066 WO 95/17524	4/18/1991 1/23/1992 6/29/1995	PCT PCT PCT				Yes Yes
	WO 92/01066 WO 95/17524 WO 95/10805	4/18/1991 1/23/1992 6/29/1995 4/20/1995	PCT PCT PCT PCT				Yes Yes Yes Yes
	WO 92/01066 WO 95/17524	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997	PCT PCT PCT PCT				Yes Yes Yes Yes Yes Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324	4/18/1991 1/23/1992 6/29/1995 4/20/1995	PCT PCT PCT PCT				Yes Yes Yes Yes Yes Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999	PCT PCT PCT PCT PCT PCT				Yes Yes Yes Yes Yes Yes Yes Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999	PCT PCT PCT PCT PCT PCT PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT PCT PCT PCT PCT PCT PCT PCT PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308 WO 99/64626	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308 WO 99/64626 WO 99/64627	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308 WO 99/64626 WO 99/64627 WO 00/33161	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308 WO 99/64626 WO 99/64627 WO 00/33161 WO 00/50639A2	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/57308 WO 99/64626 WO 99/64627 WO 00/53161 WO 00/50639A2 (cd format)	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format)	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/33161 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format)	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 12/16/1999 06/08/2000	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/33161 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format)	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 06/08/2000	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 06/08/2000	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617 BP 0245466B1	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 12/16/1999 06/08/2000	PCT				Yes   Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 12/16/1999 06/08/2000 11/29/2001 08/22/2002 5/25/1994 10/11/1989	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/05324 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64626 WO 99/64627 WO 00/33161 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617 BP 0245466B1 EP 0336560A2	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 06/08/2000 11/29/2001 08/22/2002 5/25/1994 10/11/1989	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617 BP 0245466B1 EP 0336560A2 BP 0336560A3 BP 0336560B1 BP 0404682A2	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 12/16/1999 06/08/2000 11/29/2001 08/22/2002 5/25/1994 10/11/1989	PCT				Yes
	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617 BP 0245466B1 EP 0336560A2 BP 0336560A3 BP 0336560B1	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 12/16/1999 06/08/2000 11/29/2001 08/22/2002 5/25/1994 10/11/1989 11/30/1994	PCT				Yes
Examiner	WO 92/01066 WO 95/17524 WO 95/10805 WO 97/40462 WO 99/05323 WO 99/05324 WO 99/11822 WO 99/11822 WO 99/54500 WO 99/54500 WO 99/54500 WO 99/64626 WO 99/64627 WO 00/50639A2 (cd format) WO 00/50639A3 (cd format) WO 01/91026 WO 02/064617 BP 0245466B1 EP 0336560A2 BP 0336560A3 BP 0336560B1 BP 0404682A2	4/18/1991 1/23/1992 6/29/1995 4/20/1995 10/30/1997 02/04/1999 02/04/1999 3/11/1999 10/28/1999 12/16/1999 06/08/2000 11/29/2001 08/22/2002 5/25/1994 10/11/1989 11/30/1994 12/27/1990	PCT	Date Considered	11/15/04		Yes

Serial No.: 10/019,342 Page 3 of 6

	FORM PTO	_1449		2438-4042033	10/019,342	
	. POMITIO	-1445		Applicant		
INFO	RMATION DISCLO	SURE CITATI	ON	DENTON, et al.	4-0170	
				Filing Date;	Group Art Uni	ir.
				December 21, 2001	TBA /63/	
	T 777 0 400 100 10	14069004	188			ו אינו אינו אינו אינו אינו אינו אינו אינ
mea	EP 0408188A2	1/16/1991	EP			Yes No
	EP 0408188A3	1/16/1991	BP			Yes No
	EP 0408188B1	1/16/1991	RP			Yes No
	EP 0449494A2	10/2/1991	EP			
<u> </u>	EP 0449494A3	10/2/1991	EP			Yes No
	EP 0449494B1	8/25/1999	EP		<del>-</del>	Yes No
<del></del>	EP 0474944A2	3/18/1992 7/16/1997	EP.		<del></del>	Yes No
	EP 0474944B1 EP 0481286A2	4/22/1992	EP			Yes No
		4/9/1997	BP		<del></del>	Yes No
	EP 0481286B1 EP 0494907B1	5/15/1996	EP			Ycs No
		8/31/1994	EP			Yes No
	EP 0612846A1 EP 0612846B1	8/16/2000	EP		<del></del>	Yes No
<del> </del>	EP 0673523B1	2/10/1999	HP HP		<del></del>	Yes No
1/	EP 0812922A2	12/17/1997	BP	,		Yes No
	III UGIZZZZE	1 244 7 11 7 2 2 1	1 45%			
THE STATE OF THE S	Mary D. Oleran	mer sammaren d	ALTER DESIGNATION OF			**************************************
	THE PARTY OF THE P	STORIGITATION	5 UUUUA			
	Panidet Arthur I	"100R ACHO	Drawidanta	l Address – Making Geno	mic Medicine a Reality	American Jonnal of
MAR	Human Genetics,			n veter one - white Green	THE TITOMICS OF TRANSPORT	) A DESCRIPTION OF
<del></del>	Cirrier et al "Gen	etic Control of l	True-Induc	ed Recovery from Murine	Visceral Leishmaniasi	". J. Pharm.
1	Pharmacol. 1994,		,, ng 1,,			
	Cashman Siobhar	M, et al. "The	Irish Cysti	c Fibrosis Database", You	rnal of Medical Genetic	s, Vol. 32, pp. 972-
1	975. July 1995.		_			
	Chakraborty, R. ".			etic Questions Formulated	as the Generalized Occ	rupancy Problem",
	Genetics, July 199	93, 134:953-958				
	Chiano et al. "Fin	e Genetic Mapp	ing Using L	Taplotype Analysis and the	s Missing Data Problem	i", Am. Hum. Genet.,
	1998, 62:55-60.					
1	Clark, Andrew G.	et al., "Haploty	e Structur	e and Population Genetic	Inferences From Nuclei	tide-Sequence
	Variation in Hum	an Lipoprotein L	ipase", An	nerican Journal of Human	Genetics, Vol. 63, pp. 3	95-612, 1998.
	Clark, Andrew G.	, "Inference of I	Haplotypes	from PCR-amplified Sam	ples of Diploid Popula	ions", Mol. Biol.
	Evol., 7(2):111-12	22, 1990	· · · ·	78 50 4 724 77	7	
1	Cooper, Gillian et	tal., "Network A:	nalysis of F	Iwnan Y Microsatellite Hi	piotypes", Human Mol	ecinar Cienencs, voi. 5,
	No. 11, pp. 1759-	1700, 1990,	J Z	Incomplete Data via the E	M Alamithmis V Otalia	ing Quelety Val 10
	No. 1, pp.1-38, 19		wou from	шсотрине Даш уна те в	at vikoumu ' i' bigga	ANY DANIALL ANY 32'
	Drofite at al    Etc.	de des Reactions	Croscoon	les Antigenes HLA A et B	Chez 63 Patients Attains	ts de Polvarthrite
ĺ	Rhumatoide", Rev	ль du Rimmatic	me 1984	51(4), 197-202	mitched man to Manhalate attending	~ ~ ~ a urjm, m
-	Drysdale. "Compl	lex promoter and	codino re	gion beta 2-adrenergic re	ceptor haplotypes alter	receptor expression
	and predict in vive	o responsiveness	<sup>21</sup> , 2000, Pr	roc. Natl. Acad. Sci. 97(19	):10483-8	
	Excoffict et al "	Incorporating G	snotypes of	Relatives into a Test of L	nkage Disequilibrium".	Am. J. Hum, Genet,
	62:171-180, 1998		-2 - 7			
i i	Excofficr et al. "A	faximum-Likelih	ood Estimo	ation of Molecular Haplat	ype Frequencies in a Di	ploid Populations",
	Mol, Biol Evol.	1995, 12(5):921-	-927.			
U		et al., "Biostatist	ics: A Meth	iodology for the Health Sc	<i>iences"</i> , pp. 345-495, 6	92-762, John Wiley &
-	Sons, Inc.			•	<u> </u>	10 100
Examiner				Date Considered	arti-lat	
	mpaller	/		Trans Committee Co	VI [15]04	
EXAMINER:	Inidal if rotorence conside	ned, whether or not	ritation is in c	onformance with MPRP \$609.		
	Draw line through citation	if not in conforman	oe and not co	nsidered.		
	Include copy of this form	with next communic	auon to Appl	TURUL		

Attorney Docket: 2458-4042US5

P <sub>2</sub>	Ge	4	of
2.3	KC	4	OI (

## 

	OTHER DOCUMENTS IN THE ONLY WE THEN THE STATE OF THE STAT
mpa	Gene et al., "Haplotype Frequencies of Eight Y-chromosome STR loci in Barcelona (North-East Spain)", International Journal of Legal Medicine, Vol. 112, pp. 403-405, 1999.
	Hartl, Daniel L. et al., "Genetic and Phenotypic Variation", Principles of Population Genetics, pp. 37-109, Singuer Associates, Inc., 3 ed.
	Hawley et al., "HAPLO: A Program Using the EM Algorithm to Estimate the Frequencies of Multi-site Haplotypes", L. of Heredity, 86(5), pp. 409-411, 1995
	Hill et al., "Human Genetic Variation and Its Impact on Public Health and Medicine", pp.62-74
	Hill, "Tests for Association of Gene Frequencies at Several LOCI in Random Mating Diploid Populations", Biometrics, 31, 881-888, 1975
	Hosng, Liem et al., "PAH Mutation Analysis Consortium Database: A Database for Disease-Producing and Other Allelia Variation at the Human PAH Locus", Nucleic Acids Research, Vol. 24, No. 1, pp. 127-131, 1996.
	Jackson et al., "Pharmacokinetic-Pharmacogenetic Modelling in the Detection of Polymorphisms in Xenobiotic Metabolism", 1990, Ann. Occup. Hyg. 34(6):653-662
	Judosn et al., "The Predictive Power of Haplotypes in Clinical Response", 2000, pp.1-12
	Judson, Richard, "Genetic Algorithms and Their Use in Chemistry", Roylews in Computational Chemistry, Vol. 10, pp. 1-66, 1997
	Kalow et al., "The Science of Pharmacological Variability: An essay", Clin. Pharma. & Therapetrics, Vol. 66, No. 5, pp.445-447, 1999
	Kardia et al., "An Evolutionary Perspective on the Genetic Architecture of Susceptibility to Cardiovascular Disease", pp. 231-245
	Kleyn, Patrick W. et al., "Genetic Variation as a Guide to Drug Development", Science, Vol. 281, pp. 1820-1821, September 18, 1998.
	Kwok et al., "Single Nucleotide Polymorphism Libraries: Why and How are We Building Them?", Mol. Med. Today, 1999, Vol. 5, pp. 538-543
	Layton et al., "The Therapeutic Response to D-Pentcillamine in Rheumatold Arthritis: Influence of Glutathlone S- transferase Polymorphisms", Rheumatology, 1999, 38:43-47
	Long et al., "An E-M Algorithm and Testing Strategy for Multiple-Locus Haplotypes", Am. J. Hum. Genet., 56:799-810, 1995
	MacLean et al., "Estimation of Myriad Haplotype Frequencies", Genetic Reidemiology, 2:263-272, 1985
	Magon, "Pharmacogenetic interactions in GGPD deficiency and development of an in vitro test to predict a drug's hemolytic potential", 1981, Prog. Clin. Biol. Res., 55:709-24
	Matisc, T.C., "Genome Scanning for Complex Disease Genes Using the Transmission / Disequilibrium Test and Haplotype-based Haplotype Relative Risk", Genetic Epidemiology, Vol. 12, pp. 641-645, 1995.
	Meyor, Urs A., "Medically Relevant Genetic Variation of Drug Effects", pp. 41-49
	Michalatos-Belvin et al. "Molecular Haplotyping of Genetic Markers 10 kb Apart by Allele-Specific Long Range PCR", Nucleic Acids Research, 1996, 24(23):4841-4843.
	Moti, Motomi et al., "Computer Program to Predict Likelihood of Finding an HLA-Matched Donor: Methodology, Validation, and Application". Biology of Blood and Marrow Transplantation, Vol 2, pp. 134-144, October 1996.
	Mori, Motomi et al., "HLA Gene and Haplotype Frequencies in the North American Population", Transplantation,, Vol. 64, No. 7, pp. 1017-1027, October 15, 1997.
	Neuman et al. "A Bit about Haplotypes: Using Binary Digits to Code Tightly Linked Loci", Hum. Hered., 1994 44:241-247
	Niu et al, "Bayesian Haplotype Inference for Multiple Linked Single-Nucleotide Polymorphisms", Am. J. Hum.  Genet., 2002, 70:157-169

Examiner	mealler	Date Considered	11/15/04
EXAMINER:	Initial if reference considered, whether or not citation is in conform		
	Draw line through citation (f not in conformance and not considere	d.	
	Include copy of this form with next communication to Applicant.		

	D	
	rage	5 of 6

2007DAF DECO 1440	Attorney Docket: 2458-4042US5	Scrisl No.: 10/019,342	
FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Applicant: DENTON, et al.		
MIGRIALION DISCLUSIVA CITATION	Filing Date: December 21, 2001	Group Art Unit:	

	OTHER DOCUMENTS (Including Many, our Many Influence Pages and
mos	Olscn et al., "Design and Sample-Size Considerations in the Detection of Linkage Disequilibrium with a Disease Locus", Am. J. Hum, Genet. 1994, 55:574-580
	Perlin, Mark et al., "Toward Fully Automated Genotyping: Allele Assignment, Pedigree Construction, Phase
	Determination, and Recombination Detection in Duchenne Muscular Dystrophy", American Journal of Human
<u> </u>	Genetics, Vol. 55, pp. 777-787, June 1994.
	Press, William H. et al, "Numerical Recipes in C: The Art of Scientific Computing", pp. 394-455, Cambridge University Press, 2 ed.
	Rich, Elaino et al., "Artificial Intelligence", pp. 514-519, MoGraw-Hill, Inc., 2 ed.
	Ruano et al. "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules",
	August 1990, Proc. Natl. Acad. Sci., Vol. 87, pp. 6296-6300
	R & D Directions Staff, "Beyond Genomics", R & D Directions, April 1999 pp. 40-44
	Slatkin et al., "Testing for Linkage Disequilibrium in Genotypic Data Using the Expectation-Maximization
	Algorithm", Heredity, 76:377-383, 1996
	Stacesen et al., "M235T Angiotensinogen Gene Polymorphism And Cardiovascular Renal Risk", J. Hypertension,
	January 1999, 17(1):9-17.
	J.C. Stephons et al., "Haplotype Variation and Linkage Disequilibrium in 313 Human Genes", Science, 2001
<del></del>	Stephens, J. Claiborne, "Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics",
	Molecular Diagnosis, Vol. 4, No. 4, pp. 309-317, December 1999.
	Stephens et al., "A New Statistical Method for Haplotype Reconstruction from Population Data", Am. J. Hum.
	Genet., 2001, 68:978-989
	Thayer, Ann M., "Bioinformatics for the Masses", C&EN, 19-32, 2000
	Tishkoff S. A. et al., "The Accuracy of Statistical Methods for Estimation of Haplotype Frequencies: An Example
	from the CD4 Locus", American Journal of Human Genetics, Vol 67, pp. 518-522, August 2000.
	Appleby, "Pharmaceutical Labs Exploring Drugs Tatlored to Ethnicity, DNA", January 24, 1999, Las Vegas Review  - Journal, Section A, p. 26A.
	Birt, "Drugs Industry Predicted to Be 'Microsoft' For the New Millentum", June 1, 1998, Birmingham Post, pg. 29
	"Bursting with Innovation", Decomber 1997, Med Ad News,
	Craig, "Answers for the Toughest Challenges", April 19, 1999; Forbes, Supplement; Special Advertising Section; Biotechnology, page 2.
	Debase, "California Spotlight: Incyte plans to conquer DNA mapping within year; Genetics: Part of the plan is to
	purchase British firm Hexagen for \$41 million", August 23, 1998, The Orange County Register, pg. K01.
	Furuta, "Race to Unlock Genetic Secrets Heats Up in Japan's Laboratories: Analysis of Genes Could Help Create
	Tuilor-Made Medicines", November 16, 1998, The Nikkei Weekly, pg. 1
	"Genaissance Raises \$10 Million in Private Placement; Accelerates Development of Personalized Medicines Through
	Pharmacogenomics", August 27, 1998; PR Newswire, Financial News Section
	MacGregor, "Delay is Half The Cure: Nova's Merger With U.S. Firm Steps Up Research Aimed at Postponing
<u> </u>  .	Alzheimer's Until It No Longer Matters", March 10, 1999, The Gazette (Montreal), Section D1.
	"Mix/Match Analysis of Gone Diversity in Ethnic Cross-Section Aims at Personalized Medicine", 2001, Bioworld
	Today, p. 5
	Regalado, "Inventing the Pharmacogenomics Business, Part 1", September 1997, In Vivo the Business & Medicino
	Report, p. 52.
	Sadec, Wolfgang, "Using Genetic Information to Optimize Drug Therapy", Medscape Pharmacotherapy, 2000
	"Terrapin and Genaissance Establish Research and Development Collaboration Targeting Daug Candidates Based on
	Estrogon Receptor Modulators Identified in Genomics Research", Pebruary 12, 1998, Business Wire

Examiner	mealler	Date Considered	11/15/04
HXAMINER	Initial if reference considered, whether or not citation is in conform Draw line fitningh citation if not in conformance and not considere Include copy of this form with next communication to Applicant.		

•		Page 6 of 6
FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attornoy Docket: 2458-4042US5	Serial No.: 10/019,342
	Applicant:	
	DENTON, et al. Filing Date:	Group Art Unit:
	December 21, 2001	TBA 1631

	OTHER DOCUMENTS TO SUMME AND AND THE PROPERTY OF THE PROPERTY				
mea	The Genesis Group, "Will Pharmocogenomics Create a \$2 Button Market?", July 1996, Genesis Report 5(1), pg 20, 1061-2289				
	"Valigon Acquires Berlin-Based Infogon and Phenotype Database", 2000, Worldwide Biotech				
	"Variagenics, Inc. Acquires Exclusive Rights To Leading Pharmacogenomic Technologies for Neurological Disorders", February 8, 1999, Canada Newswire				
	Yasuhara, "Ethnic factors in evaluation of drug efficacy and safety", August 1994, Nippon Yakurigaku Zasshi, 102(2): 67-78 (English Abstract)				
	Text of April 17, 2001 press release to: Classen patent No. 6,219,674				
· · · · ·					
<del> </del>					
<del></del>					

Examiner	mpfeller	Date Considered	11/15/04	
EXAMINER:	Initial if reference considered, whether or not officien is in conform	ance with MPEP \$609.	7	
	Draw line through obtation if not in conformance and not considered			
	Include copy of this form with next communication to Applicant.			